GoodRx Holdings, Inc. (GDRX) Stock Forecast
GDRX analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.36 / 5 from 14 analysts
- Price target
- $3.95 average of analyst targets
- Upside to target
- +17.6% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $0.04
- 52-week range
- $1.87 – $3.98
GDRX analyst ratings
14 analystsNumber of analysts at each rating.
GDRX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
GDRX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.08 | $0.07 | $0.10 | $0.08 | −2.7% | 11 |
| Current fiscal year (2026) | $0.30 | $0.29 | $0.34 | $0.35 | −13.4% | 11 |
| Next fiscal year (2027) | $0.35 | $0.30 | $0.45 | $0.30 | +16.2% | 11 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
GDRX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $202.1M | $199.1M | $205.4M | +3.1% | 12 |
| Current fiscal year (2026) | $798.5M | $790.7M | $802.4M | +0.2% | 13 |
| Next fiscal year (2027) | $836.2M | $809.0M | $850.9M | +4.7% | 13 |
GDRX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
GDRX revenue: reported and forecast
GDRX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | −2.3% | 3 up · 4 down |
| Current fiscal year (2026) | $0.31 | $0.30 | $0.30 | $0.30 | $0.30 | −1.9% | 4 up · 5 down |
| Next fiscal year (2027) | $0.36 | $0.36 | $0.36 | $0.35 | $0.35 | −1.7% | 6 up · 5 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
GDRX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; GDRX beat in 5 of 12.
What analysts expect from GDRX
14 analysts cover GoodRx; their consensus rating is hold (3.36 on a 1–5 scale, where 5 is a strong buy). The average price target is $3.95, 17.6% above the latest close of $3.36. Analysts expect earnings of $0.30 per share for 2026, −13.4% from a year earlier. For 2027 the average estimate is $0.35 per share on revenue of $836.2 million. GoodRx beat the EPS estimate in 5 of the last 12 quarters.
Related: GDRX income statement, GDRX key metrics, GDRX chart. See the GDRX stock overview for the latest quote and news.
GDRX forecast FAQ
What is GoodRx's price target?
The average analyst price target for GoodRx is $3.95, 17.6% above the latest close of $3.36.
Is GoodRx a buy, hold or sell?
Of 14 analysts covering GoodRx, 3 rate it a strong buy, 1 a buy, 8 a hold, 2 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is GoodRx's EPS forecast?
Analysts forecast $0.30 per share for 2026 (range $0.29 to $0.34); for 2027 the estimate is $0.35.
What is GoodRx's revenue forecast?
The average revenue estimate for 2026 is $798.5 million, growth of 0.2%; for 2027 it is $836.2 million.
When does GoodRx report earnings?
GoodRx is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 after the market closes; the EPS estimate is $0.04.
Does GoodRx usually beat earnings estimates?
GoodRx reported EPS at or above the analyst estimate in 5 of the last 12 quarters.